A major meta-analysis of 3.9 million pregnancies has revealed mixed evidence regarding the relationship between prenatal asthma medications and autism spectrum disorder in children. The comprehensive review, published in PLOS Medicine, synthesized data from eight rigorous studies conducted over two decades to evaluate whether common asthma treatments affect child neurodevelopment.
While some studies suggested potential associations with beta-2-adrenergic agonists—the most frequently prescribed asthma medications during pregnancy—the overall evidence remains inconsistent across populations and study designs. Importantly, researchers emphasize that the documented benefits of maintaining adequate asthma control during pregnancy for both maternal and fetal health substantially outweigh the uncertain developmental risks identified in this analysis.
These findings underscore the importance of individualized clinical decision-making, where pregnant women with asthma should continue working closely with their healthcare providers to optimize treatment strategies.
Was this article helpful?
